945917-91-9

Upstream product

• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 106-40-1 4-bromo-aniline 

Downstream Products

• 1078791-16-8 (S)-N-(4-bromophenyl)pyrrolidine-2-carboxamide 
• 1401065-87-9 methyl (S)-2-(2-(4-bromophenylcarbamoyl)pyrrolidine-1-carbonyl)phenylcarbamate 
• 1219632-35-5 C₂₂H₂₄BrN₃O₄ 

Relevant academic research and scientific papers

CAL-B-mediated efficient synthesis of a set of valuable amides by direct amidation of phenoxy- and aryl-propionic acids

An efficient, easy and sustainable amidation of a set of non-activated carboxylic acids with anilines, assisted by CAL-B, as biodegradable catalyst, is reported. The enzymatic amidation reactions are performed on set of nonsteroidal anti-inflammatory drugs (NSAIDs), phenoxypropionic acid and protected-prolines by direct condensation of one equivalent of carboxylic acids and two equivalents of anilines derivatives in heptane after 72?h of reaction at 80?°C. The obtained carboxylic amides are recovered with isolated chemical yields varied between moderate and excellent. Fourteen from them are reported for the first time, and an X-ray crystal is obtained for: N-(4-iodophenyl)-2-(4-isobutylphenyl)propanamide 1d.

Balancing interactions in proline-based receptors for chiral recognition of l-/d-DOPA

Proline based receptors (1-14) attached with phenylboronic acid and benzaldehyde binding groups at the N-/C-or C-/N-termini of the proline residue were created for chiral recognition of l-/d-DOPA, in an attempt to examine if balancing the two binding even

Proline-Based Boronic Acid Receptors for Chiral Recognition of Glucose

Chiral recognition remains a major challenge in the area of molecular receptor design. With this research, we set out to explore the use of proline-based receptors for chiral recognition. Importantly, the proline structure allows for the introduction of a

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

INHIBITORS OF HCV NS5A

The present invention provides compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

The ant-pro reverse-turn motif. Structural features and conformational characteristics

This article details the characteristic conformational features of the Ant-Pro reverse turn - a folded pseudo β-turn motif that displays a closed nine-membered-ring hydrogen-bonded network involving just two amino acid residues, namely anthranilic acid (A

A PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST

A process for resolving a compound in racemic form comprising the following steps is described: a) reacting a compound in racemic form with a resolving agent, b) forming a diastereoisomeric complex of the resolving agent and an enantiomer of interest, c} separating the enantiomer of interest from the obtained diastereoisomer, wherein such a process is characterized in that said resolving agent is a compound of Formula (I). A diastereoisomeric complex between the resolving agent of Formula (I) and the enantiomer of interest is also described. The process according to the invention allows acid and basic racemic mixtures to be separated.